Argen X【ARGX】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

604.60

買値

587.00

売値

605.60

出来高

10,016

596.20 日の範囲 604.60

322.50 52 週間の範囲 613.00

時価総額

35.789B

前日終値

595.40

始値

599.60

時刻

604.6

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

60,030

発行済株式数

59,194,000

配当利回り

PER

-121.30

1 株当たり利益 (EPS)

-4.98

歳入

1.27B

純利益

-295.05M

セクター

Coml Physical, Biologcl Resh

業界

Coml Physical, Biologcl Resh

ウェブサイト

www.argenx.com

本社

Amsterdam, North Holland, Nld

設立

Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the ユーロネクスト with ticker ARGX. The last closing price for Argen X was 595.40 €. Over the last year, Argen X shares have traded in a share price range of 322.50 € to 613.00 €.

Argen X currently has 59,194,000 shares in issue. The market capitalisation of Argen X is 35.24 € billion. Argen X has a price to earnings ratio (PE ratio) of -121.30.

argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for...

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx...

argenx to Participate at Upcoming Investor Conferences

November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference...

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced...

argenx to Present at Upcoming Investor Conferences

August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	4.8	0.800266755585	599.8	613	586.4	82795	602.81527959	DE
4	21.8	3.74056280027	582.8	613	572.8	54932	594.07235078	DE
12	118.9	24.4801317686	485.7	613	470.3	60030	552.15297909	DE
26	210	53.2184490623	394.6	613	394.2	62487	496.78415198	DE
52	262.7	76.8353319684	341.9	613	322.5	60320	428.67740876	DE
156	295.6	95.6634304207	309	613	224.1	65077	377.89327516	DE
260	457.6	311.292517007	147	613	93.05	74397	299.23174749	DE

ARGX - Frequently Asked Questions (FAQ)

What is the current Argen X share price?

The current share price of Argen X is 604.60 €

How many Argen X shares are in issue?

Argen X has 59,194,000 shares in issue

What is the market cap of Argen X?

The market capitalisation of Argen X is EUR 35.24B

What is the 1 year trading range for Argen X share price?

Argen X has traded in the range of 322.50 € to 613.00 € during the past year

What is the PE ratio of Argen X?

The price to earnings ratio of Argen X is -121.3

What is the cash to sales ratio of Argen X?

The cash to sales ratio of Argen X is 28.21

What is the reporting currency for Argen X?

Argen X reports financial results in USD

What is the latest annual turnover for Argen X?

The latest annual turnover of Argen X is USD 1.27B

What is the latest annual profit for Argen X?

The latest annual profit of Argen X is USD -295.05M

What is the registered address of Argen X?

The registered address for Argen X is LAARDERHOOGTWEG 25, AMSTERDAM, NORTH HOLLAND, 1101 EB

What is the Argen X website address?

The website address for Argen X is www.argenx.com

Which industry sector does Argen X operate in?

Argen X operates in the COML PHYSICAL, BIOLOGCL RESH sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
EIFDSTour Eiffel DS	0.0432 € (800.00%)	89.74k
SEQUASequana medical NV	2.76 € (33.33%)	1.64M
ALEUPEuroplasma	0.0484 € (28.38%)	6.54M
ALPAUPaulic Meunerie SA	1.43 € (16.26%)	17.14k
GNROGeNeuro SA	0.081 € (15.38%)	330.33k
MLSMLSmalto	0.0125 € (-32.43%)	50
ALVIAVialife Sa	13.30 € (-27.72%)	7
MLMADMade	9.25 € (-15.91%)	255
ALALOAcheterLouerFR	0.23 € (-14.81%)	3.92k
ALLPLLepermislibre SA	0.397 € (-11.78%)	3.01k
ATOAtos SE	0.0023 € (-4.17%)	396.59M
BCPBanco Comercial Portugues SA	0.451 € (0.16%)	17.85M
LATLatecoere	0.0094 € (3.30%)	9.13M
ALVERVergnet	0.0021 € (-4.55%)	8.37M
ALEUPEuroplasma	0.0484 € (28.38%)	6.54M